JPWO2022189942A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022189942A5 JPWO2022189942A5 JP2023555245A JP2023555245A JPWO2022189942A5 JP WO2022189942 A5 JPWO2022189942 A5 JP WO2022189942A5 JP 2023555245 A JP2023555245 A JP 2023555245A JP 2023555245 A JP2023555245 A JP 2023555245A JP WO2022189942 A5 JPWO2022189942 A5 JP WO2022189942A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- cancer
- formulation
- seq
- bispecific anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158552P | 2021-03-09 | 2021-03-09 | |
| US63/158,552 | 2021-03-09 | ||
| PCT/IB2022/052009 WO2022189942A1 (en) | 2021-03-09 | 2022-03-07 | Treatment of cancers lacking egfr-activating mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024509920A JP2024509920A (ja) | 2024-03-05 |
| JP2024509920A5 JP2024509920A5 (https=) | 2025-03-13 |
| JPWO2022189942A5 true JPWO2022189942A5 (https=) | 2025-03-13 |
Family
ID=80738936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555245A Pending JP2024509920A (ja) | 2021-03-09 | 2022-03-07 | Ｅｇｆｒ活性化変異を欠くがんの治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220298248A1 (https=) |
| EP (1) | EP4304644A1 (https=) |
| JP (1) | JP2024509920A (https=) |
| KR (1) | KR20230156094A (https=) |
| CN (1) | CN116997358A (https=) |
| AU (1) | AU2022233518A1 (https=) |
| BR (1) | BR112023018278A2 (https=) |
| CA (1) | CA3212669A1 (https=) |
| CL (2) | CL2023002663A1 (https=) |
| IL (1) | IL305700A (https=) |
| JO (1) | JOP20230211A1 (https=) |
| MX (1) | MX2023010633A (https=) |
| WO (1) | WO2022189942A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300854A (en) | 2020-08-25 | 2023-04-01 | Janssen Biotech Inc | Treatment of non-small cell lung cancer with EGFR mutations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP1766068A4 (en) | 2004-06-04 | 2010-03-03 | Genentech Inc | EGFR Mutations |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| CN113201073A (zh) * | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| EP2977464A4 (en) * | 2013-03-19 | 2016-10-19 | Toppan Printing Co Ltd | PROCEDURE FOR PREDICTING SENSITIVITY TO EGFR HEMMER |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| SG11202108311RA (en) * | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
-
2022
- 2022-03-07 IL IL305700A patent/IL305700A/en unknown
- 2022-03-07 CA CA3212669A patent/CA3212669A1/en active Pending
- 2022-03-07 EP EP22710172.2A patent/EP4304644A1/en not_active Withdrawn
- 2022-03-07 CN CN202280019912.6A patent/CN116997358A/zh active Pending
- 2022-03-07 BR BR112023018278A patent/BR112023018278A2/pt unknown
- 2022-03-07 WO PCT/IB2022/052009 patent/WO2022189942A1/en not_active Ceased
- 2022-03-07 US US17/687,984 patent/US20220298248A1/en active Pending
- 2022-03-07 MX MX2023010633A patent/MX2023010633A/es unknown
- 2022-03-07 KR KR1020237034184A patent/KR20230156094A/ko active Pending
- 2022-03-07 JP JP2023555245A patent/JP2024509920A/ja active Pending
- 2022-03-07 AU AU2022233518A patent/AU2022233518A1/en not_active Abandoned
-
2023
- 2023-09-06 CL CL2023002663A patent/CL2023002663A1/es unknown
- 2023-09-07 JO JOJO/P/2023/0211A patent/JOP20230211A1/ar unknown
-
2024
- 2024-04-17 CL CL2024001201A patent/CL2024001201A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024153659A5 (https=) | ||
| KR102905497B1 (ko) | 항체-약물 컨쥬게이트와 parp 저해제의 조합 | |
| JP2024161445A (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| JP7769032B2 (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| JP7783182B2 (ja) | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 | |
| WO2019230645A1 (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療 | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| JP7761490B2 (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物 | |
| CN118401259A (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| JPWO2020174370A5 (https=) | ||
| Yasui et al. | Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16 | |
| US20080008704A1 (en) | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies | |
| JPWO2021161262A5 (https=) | ||
| JPWO2022189942A5 (https=) | ||
| US20220298248A1 (en) | Treatment of Cancers Lacking EGFR- Activating Mutations | |
| CA3141174A1 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| JPWO2022043895A5 (https=) | ||
| Van Cutsem | Optimizing Administration of Epidermal Growth Factor Receptor–Targeted Agents in the Treatment of Colorectal Cancer | |
| JPWO2020230091A5 (https=) | ||
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| HK40102929A (zh) | 对缺失egfr激活突变的癌症的治疗 | |
| WO2025087386A1 (zh) | 抗her2抗体药物偶联物治疗乳腺癌的用途 | |
| EA050376B1 (ru) | ЛЕЧЕНИЕ ПАЦИЕНТОВ, ИМЕЮЩИХ МУТАЦИИ, ВЫЗЫВАЮЩИЕ ПРОПУСК ЭКЗОНА 14 В c-Met | |
| EA053135B1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство |